Abstract
We report the first total synthesis of the limonoid andirolide N using a 12-step sequence from commercially available materials. The final step of this route demonstrates the chemical feasibility of our biosynthetic proposal that andirolide N arises from 8α-hydroxycarapin. The strategic use of a degraded limonoid as a platform for the synthesis of more structurally complex congeners may be a general approach to obtain limonoids with diverse functional properties.
Andirolide N (5), a limonoid tetranortriterpenoid natural product isolated from the flowers of a mahogany tree indigenous to the Amazonian rainforest (Carapa guianensis), possesses a synthetically demanding bicyclo[3.3.1]nonane ring system with a bridging tetrahydrofuran ring appended.1,2 Decades of limonoid synthetic investigations3 have been motivated by the wide range of their biological properties,4 including antimalarial,1 anticancer,5 and anti-inflammatory activities.6 Recent reports have also demonstrated exciting neuroprotective and regenerative properties.7 Herein, the first total synthesis of the limonoid andirolide N (5) is reported by chemical conversion from the limonoid 8α-hydroxycarapin (6), which demonstrates the chemical feasibility of this pathway as a possible mode of biosynthesis (Figure 1). To generate these limonoids, as well as to allow access to a multitude of limonoids with differing A-ring structures, this approach utilizes a late-stage introduction of the limonoid A-ring: a location of great chemical diversity in this class of natural products as exemplified by compounds 1−6.8
Figure 1.

Synthetic approach to andirolide N (5) via iso-odoratin (7).
While many limonoids, including andirolide N (5), are trace isolates from threatened rainforest environments, availability from citrus and neem fruits has allowed for investigations of some members of the limonoid class through the use of semisynthesis and relay synthesis.9 Independent, contemporaneous studies in the early 1970s by the groups of Connolly and Ekong10 examined the biomimetic oxidative fragmentation of the limonoid B-ring and reassembly through a 1,6-conjugate addition to form mexicanolide (3). Williams and co-workers recently completed a total synthesis of mexicanolide (3) through employment of an analogous 1,6-conjugate addition strategy.11 Additionally, a relay synthesis of azadirachtin reported by Ley took advantage of the availability of this natural product from neem oil.12
A landmark total synthesis of azadiradione was reported by Corey and Hahl that used a polyene cyclization to form the skeleton of azadiradione in a stereocontrolled manner.13 An alternative polycyclization strategy was developed for the groundbreaking synthesis of limonin (1) by Yamashita, Hayashi, Hirama and co-workers.14 Additionally, Corey and Behenna reported the synthesis of a protolimonoid by polyolefin cyclization; the protolimonoid was suggested to be a precursor to all known limonoids through systematic biomimetic oxidation and rearrangement reactions.15
We developed a general synthetic approach to access limonoids with differing A-ring structures, such as those in Figure 1, by envisioning that these materials might arise from the degraded limonoid iso-odoratin (7),16 the Δ8(14) isomer of the natural product odoratin.17 For the synthesis of 8α-hydroxycarapin (6), the bicyclo[3.3.1]nonane could be forged through an acylation− Michael addition strategy using a suitable electrophile. Retro-synthetic design via 8α-hydroxycarapin (6) would provide a means to test our hypothesis that this material can lead to andirolide N (5). To study the feasibility of this biosynthetic relationship and forming a bicyclo[3.3.1]nonane by this approach, we developed a route to iso-odoratin through the assembly of three simple building blocks (8−10).
The synthesis of iso-odoratin (7) is described in Scheme 1 and begins with a diastereoselective aldol reaction with 3-furaldehyde (9) and 6-methylcyclohexenone (8), the latter prepared from commercially available dihydrocarvone in one step,18 to provide 12 in 72% yield after the intermediate alkoxide, 11, was treated with AcCl. Use of a Rawal-type diene (10)19 elicited a thermal Diels−Alder reaction with 12 to form the adduct 13, as an uncharacterized mixture of diastereomers. An intramolecular acetate aldol and β-elimination of the dimethylamino group was performed with KHMDS to form the intermediate 14. Upon treatment of the organic extracts with TsOH, 15 was formed by desilylation and dehydration. The conversion of 12 to 15 over two steps proceeds in an excellent 40% overall yield to provide 15 as an inconsequential mixture of diastereomers at C10 (1:1 dr). The structures of 15 and epi-15 were confirmed by X-ray crystallography and NOESY NMR experiments, respectively.
Scheme 1. Scalable Synthesis of iso-Odoratin (7)a.

aReagents and conditions: (a) i-Pr2NH (1.25 equiv), n-BuLi (1.1 equiv), 3-furaldehyde (9) (1.05 equiv), −78 °C, THF, 0.5 h, then AcCl (1.3 equiv), −78 to −30 °C, 72%; (b) 10 (2.5 equiv), PhCF3, 120 °C, 14 h; (c) KHMDS (2.0 equiv), −78 °C, 1.5 h, then TsOH (1.0 equiv), 1 h, 23 °C, 40% over 2 steps; (d) Karstedt’s Catalyst (0.3 mol %), Et3SiH (2.0 equiv), PhMe, 90 °C, 2.5 h, 77%.
This mixture of diastereomers was subjected to Karstedt’s catalyst (tris(tetramethyldivinyldisiloxane)diplatinum)20 and Et3SiH, which cleanly afforded iso-odoratin (7) as a single diastereomer in 77% yield after acidic aqueous workup. The use of Et3SiH was more efficient than the use of other silanes (TIPSiH, DMPSiH, TMDS, or PMHS), which correlates with previously observed differences in rates of hydrosilylation with Karstedt’s catalyst.20,21 It is noteworthy that commonly employed conditions for enone reduction were not successful for reducing the doubly vinylogous 1,7-dicarbonyl compound, in part owing to the propensity for many reagents to deprotonate this substrate (15), rather than effect an alkene reduction. Formation of the extended enolate of 15 was confirmed by quenching purple reaction mixtures with deuterated solvent resulting in loss of color and incorporation of deuterium. The four-step sequence to convert 6-methylcyclohexenone (8) to iso-odoratin (7) proceeds in 22% overall yield and can produce decagram quantities of 7 per batch.
The regio- and stereoselective hydroxylation of C8 of the limonoid framework is a well-established problem in the semisynthesis literature.22 Specifically, the oxidation of odoratin is known to lead to aromatization of the leftmost ring of odoratin, the limonoid B-ring. This established challenge guided us to employ iso-odoratin (7) as an alternative synthetic intermediate. Detailed, empirical studies established that the C8 hydroxyl group could be installed directly by treating the crude reduction mixture that contains iso-odoratin (7) with O2, P(OMe)3, and DBU (Scheme 2). This formal alkene hydration results in the formation of 16 as a single regioisomer and diastereomer after TMS ether formation. The product of hydroxylation to form the cis-decalin arrangement present in 8α-hydroxycarapin (6) was confirmed by analysis of NOESY and X-ray diffraction data.
Scheme 2. Total Synthesis of Andirolide N (5) via the Presumed Biosynthetic Precursor 8α-Hydroxycarapin (6)a.

aReagents and conditions: (a) Karstedt’s Catalyst (0.3 mol %), Et3SiH (2.0 equiv), PhMe, 90 °C, 2.5 h, then DBU (2.0 equiv), P(OMe)3 (1.5 equiv), O2 (1 atm), MeCN, 35 °C, 2 h, 52%; (b) TMSCl (1.5 equiv), imid. (3.5 equiv), CH2Cl2, 23 °C, 3 h, 60%; (c) LiHMDS (1.5 equiv), 17 (1.1 equiv), Et2O−THF (4:1), −78 to 0 °C, 1 h, 76%; (d) Cs2CO3 (2.5 equiv), allyl iodide (1.7 equiv), acetone, 56 °C, 12 h, 86%; (e) Pd(dppf)Cl2 (6 mol %), Et3N (1.5 equiv), CO (1 atm), MeOH−DMF (5:1), 60 °C, 0.5 h, 85%; (f) KHMDS (2.0 equiv), PhMe−THF (1:3), −78 to 23 °C, 0.5 h, 56%; (g) PdCl2(MeCN)2 (15 mol %), PhH, 60 °C, 2 h, 80%; (h) OsO4 (5 mol %), Oxone (2.5 equiv), 23 °C, 7 h, then aq. H2SO4, 0.5 h, 48%.
Installation of the bicyclo[3.3.1]nonane was initiated by acylation of the lithium enolate derived from 16 and the acyl cyanide 1723 to provide 18 in 76% yield. The use of an acylation strategy24 rather than an aldol and oxidation approach allowed for a redox-neutral25 installation of the 1,3-dicarbonyl functionality, as well as preclusion of retro-aldol and aldol condensation side reactions. Before the Michael addition to construct the bicyclo-[3.3.1]nonane could be performed, the 1,3-diketone group required a blocked α-position, such that the γ-position (C10) could be deprotonated and subsequently engage the pendant enoate. Although numerous conventional blocking groups were investigated (e.g., −OR, −SR, or −X),26 it was eventually found that a carbon-based blocking group allowed for formation of the bicycle. Thus, α-allylation with allyl iodide and Cs2CO3 provided the intermediate 19 as a single diastereomer, where allylation occurred from the less hindered convex face, enforcing the necessary geometry for the bicyclo[3.3.1]nonane synthesis. The allylation product 19 underwent palladium-catalyzed carbome-thoxylation with Pd(dppf)Cl2, CO, and methanol to afford the precursor to the Michael addition (20).
In addition to the challenge associated with forming a quaternary center at C10, the Michael addition is further impeded by the presence of syn-pentane interactions with the axially disposed B-ring substituents. However, the reactive potassium enolate proved to be effective for forming the sterically congested bicyclo[3.3.1]nonane: the bridgehead allylated analog of 8α-hydroxycarapin (21) was obtained in 56% yield by treatment of 20 with KHMDS. Additionally, this protocol conveniently resulted in concomitant TMS deprotection. Removal of the allyl group present in 21 was planned through alkene isomerization, oxidative cleavage, and Barton decarboxylation to reach 8α-hydroxycarapin. The alkene isomerization reaction was performed using PdCl2(MeCN)2 in benzene to provide the internal alkene isomer, iso-21.27,28
Subjection of the alkene isomer of 21 to oxidative cleavage conditions developed by Borhan and co-workers29 resulted in smooth conversion of the starting material, which after acidic aqueous workup provided andirolide N (5) directly in 48% yield. Although several mechanistic explanations could be advanced for the preceding observation, we propose that decarboxylation of 22 occurs spontaneously under the reaction conditions to give 8α-hydroxycarapin (6), which upon workup with aqueous 3 M H2SO4 undergoes a stereochemical inversion via a stabilized carbocation conjugated to the neighboring enoate to lead to the diastereomeric alcohol of 8α-hydroxycarapin, 23. The diastereomeric alcohol 23 may then undergo ketalization to form the thermodynamically favored ketal isomer.
Support for this hypothesis derives from a series of experimental observations. Aqueous workup of the oxidative cleavage reaction with saturated aqueous NaHCO3 provided 8α-hydroxycarapin (6), demonstrating the intermediacy of this natural product. When 8α-hydroxycarapin (6) was subjected to conditions analogous to the aqueous workup of the oxidative cleavage reaction, andirolide N (5) was produced as the major product. As an alternative possibility, the opposite order of events could occur, wherein hydration of the ketone precedes the inversion of configuration of the C8 stereocenter. However, further studies are required to distinguish between these mechanistic pathways.
In conclusion we have developed a 12-step synthesis of the limonoid andirolide N (5) from commercially available dihydrocarvone through employment of an acylation-Michael strategy for bicyclo[3.3.1]nonane construction from the degraded limonoid iso-odoratin (7). The unique tetrahydrofuran appended to the bicyclic structure of the carbocyclic skeleton of andirolide N was installed via an acid-mediated reorganization of 8α-hydroxycarapin (6). While these studies demonstrate the chemical feasibility that 8α-hydroxycarapin could be the biosynthetic precursor to andirolide N, whether or not the polycyclic structure of andirolide N is formed in nature by this pathway remains unknown.
Supplementary Material
Acknowledgments
Dr. Brandon Mercado is gratefully acknowledged for X-ray crystallography of compounds 15 and 16. Yale University and the NSF (GRF to A.W.S.) are acknowledged for financial support.
Footnotes
Supporting Information
The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/jacs.6b12268.
Experimental procedures, X-ray diffraction, spectroscopic data for all new compounds including 1H and 13C NMR spectra (PDF)
Crystallographic data (CIF, CIF)
ORCID
Timothy R. Newhouse: 0000-0001-8741-7236
Notes
The authors declare no competing financial interest.
References
- 1.For the isolation of andirolide N, see:; Tanaka Y, Sakamoto A, Inoue T, Yamada T, Kikuchi T, Kajimoto T, Muraoka O, Sato A, Wataya Y, Kim HS, Tanaka R. Tetrahedron. 2012;68:3669–3677. [Google Scholar]
- 2.For the isolation of 8α-hydroxycarapin, see:; (a) Adesogan EK, MacLachlan LK, Taylor DAH. S Afr J Chem. 1987;40:25–29. [Google Scholar]; (b) Lin BD, Yuan T, Zhang CR, Dong L, Zhang B, Wu Y, Yue JM. J Nat Prod. 2009;72:2084–2090. doi: 10.1021/np900522h. [DOI] [PubMed] [Google Scholar]
- 3.For a review on limonoid total synthesis, see:; Heasley B. Eur J Org Chem. 2011;2011:19–46. [Google Scholar]
- 4.For reviews on limonoid biological activity, see:; (a) Champagne DE, Koul O, Isman MB, Scudder GGE, Towers GHN. Phytochemistry. 1992;31:377–394. [Google Scholar]; (b) Saraf S, Roy A. Biol Pharm Bull. 2006;29:191–201. doi: 10.1248/bpb.29.191. [DOI] [PubMed] [Google Scholar]
- 5.For reviews on limonoid anticancer activity, see:; (a) Miller EG, Porter JL, Binnie WH, Guo YI, Hasegawa S. J Agric Food Chem. 2004;52:4908–4912. doi: 10.1021/jf049698g. [DOI] [PubMed] [Google Scholar]; (b) Subapriya R, Nagini S. Curr Med Chem − Anti-Cancer Agents. 2005;5:1–7. doi: 10.2174/1568011053174828. [DOI] [PubMed] [Google Scholar]; (c) Ejaz S, Ejaz A, Matsuda K, Lim CW. J Sci Food Agric. 2006;86:339–345. [Google Scholar]
- 6.Yu J, Wang L, Walzem RL, Miller EG, Pike LM, Patil BS. J Agric Food Chem. 2005;53:2009–2014. doi: 10.1021/jf0484632. [DOI] [PubMed] [Google Scholar]
- 7.For recent reports on neurologically active limonoids, see:; (a) Jang SW, Liu X, Chan CB, France SA, Sayeed I, Tang W, Lin X, Xiao G, Andero R, Chang Q, Ressler KJ, Ye K. PLoS One. 2010;5:e11528. doi: 10.1371/journal.pone.0011528. [DOI] [PMC free article] [PubMed] [Google Scholar]; (b) Hett EC, Slater LH, Mark KG, Kawate T, Monks BG, Stutz A, Latz E, Hung DT. Nat Chem Biol. 2013;9:398–405. doi: 10.1038/nchembio.1236. [DOI] [PMC free article] [PubMed] [Google Scholar]; (c) English AW, Liu K, Nicolini JF, Mulligan AM, Ye K. Proc Natl Acad Sci U S A. 2013;110:16217–16222. doi: 10.1073/pnas.1303646110. [DOI] [PMC free article] [PubMed] [Google Scholar]; (f) Li H, Li Y, Wang X, Pang T, Zhang L, Luo J, Kong L. RSC Adv. 2015;5:40465–40474. [Google Scholar]
- 8.Tan Q, Luo X. Chem Rev. 2011;111:7437–7522. doi: 10.1021/cr9004023. [DOI] [PubMed] [Google Scholar]
- 9.(a) Connolly JD, McCrindle R, Overton KH. Chem Commun. 1965:162–163. [Google Scholar]; (b) Bevan CWL, Powell JW, Taylor DAH, Halsall TG, Toft P, Welford M. J Chem Soc C. 1967:163–170. [Google Scholar]; (b) Connolly JD, McCrindle R, Overton KH. Tetrahedron. 1968;24:1489–1495. [Google Scholar]; (c) Connolly JD, Thornton IMS, Taylor DAH. J Chem Soc D. 1970:1205. [Google Scholar]; (d) Connolly JD, Overton KH, Polonsky J. In: Progress in Phytochemistry. Reinhold L, Liwschitz Y, editors. Vol. 2. Interscience Publishers; New York: 1970. pp. 385–455. [Google Scholar]; (e) Kehrli ARH, Taylor DAH, Niven M. J Chem Soc, Perkin Trans 1. 1990:2057–2065. [Google Scholar]; (f) Kehrli ARH, Taylor DAH. J Chem Soc, Perkin Trans 1. 1990:2067–2070. [Google Scholar]; (g) Grigorjeva L, Liepinsh E, Razafimahefa S, Yahorau A, Yahorava S, Rasoanaivo P, Jirgensons A, Wikberg JES. J Org Chem. 2014;79:4148–4153. doi: 10.1021/jo500318w. [DOI] [PubMed] [Google Scholar]
- 10.(a) Connolly JD, Thornton IMS, Taylor DAH. J Chem Soc D. 1971:17–18. [Google Scholar]; (b) Obasi ME, Okogun JI, Ekong DEU. J Chem Soc, Perkin Trans 1. 1972:1943–1946. [Google Scholar]; (c) Connolly JD, Thornton IMS, Taylor DAH. J Chem Soc, Perkin Trans 1. 1973:2407–2413. [Google Scholar]
- 11.(a) Faber JM, Williams CM. Chem Commun. 2011;47:2258–2260. doi: 10.1039/c0cc04698a. [DOI] [PubMed] [Google Scholar]; (b) Schuster H, Martinez R, Bruss H, Antonchick AP, Kaiser M, Schurmann M, Waldmann H. Chem Commun. 2011;47:6545–6547. doi: 10.1039/c1cc11388g. [DOI] [PubMed] [Google Scholar]; (c) Faber JM, Eger WA, Williams CM. J Org Chem. 2012;77:8913–8921. doi: 10.1021/jo301182f. [DOI] [PubMed] [Google Scholar]
- 12.Veitch GE, Beckmann E, Burke BJ, Boyer A, Maslen SL, Ley SV. Angew Chem, Int Ed. 2007;46:7629–7632. doi: 10.1002/anie.200703027. [DOI] [PubMed] [Google Scholar]
- 13.(a) Corey EJ, Reid JG, Myers AG, Hahl RW. J Am Chem Soc. 1987;109:918–919. [Google Scholar]; (b) Corey EJ, Hahl RH. Tetrahedron Lett. 1989;30:3023–3026. [Google Scholar]
- 14.Yamashita S, Naruko A, Nakazawa Y, Zhao L, Hayashi Y, Hirama M. Angew Chem, Int Ed. 2015;54:8538–8541. doi: 10.1002/anie.201503794. [DOI] [PubMed] [Google Scholar]
- 15.Behenna DC, Corey EJ. J Am Chem Soc. 2008;130:6720–6721. doi: 10.1021/ja802376g. [DOI] [PubMed] [Google Scholar]
- 16.For a description of structure-goal strategies, see:; Corey EJ, Cheng XM. The Logic of Chemical Synthesis. Wiley; New York: 1989. [Google Scholar]
- 17.Chan WR, Taylor DR, Aplin RT. Chem Commun. 1966:576–577. [Google Scholar]
- 18.For a scalable procedure of 6-methylcyclohexenone (8) synthesized from dihydrocarvone in one step, see:; Huang D, Schuppe AW, Liang MZ, Newhouse TR. Org Biomol Chem. 2016;14:6197–6200. doi: 10.1039/c6ob00941g. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Compound 10 was prepared in two steps. See the Supporting Information for details.
- 20.Johnson CR, Raheja RK. J Org Chem. 1994;59:2287–2288. [Google Scholar]
- 21.Stein J, Lewis LN, Gao Y, Scott RA. J Am Chem Soc. 1999;121:3693–3703. [Google Scholar]
- 22.Chan WR, Taylor DR, Aplin RT. Tetrahedron. 1972;28:431–437. [Google Scholar]
- 23.Compound 17 was prepared in five steps. See the Supporting Information for details.
- 24.(a) Mander LN, Sethi SP. Tetrahedron Lett. 1983;24:5425–5428. [Google Scholar]; (b) Tang Q, Sen SE. Tetrahedron Lett. 1998;39:2249–2252. [Google Scholar]
- 25.Burns NZ, Baran PS, Hoffmann RW. Angew Chem, Int Ed. 2009;48:2854–2867. doi: 10.1002/anie.200806086. [DOI] [PubMed] [Google Scholar]
- 26.For an example of blocking the α-position of a 1,3-dicarbonyl compound in total synthesis, see:; Corey EJ, Li W, Nagamitsu T. Angew Chem, Int Ed. 1998;37:1676–1679. doi: 10.1002/(SICI)1521-3773(19980703)37:12<1676::AID-ANIE1676>3.0.CO;2-T. [DOI] [PubMed] [Google Scholar]
- 27.(a) Sen A, Lai TW. Inorg Chem. 1981;20:4036–4038. [Google Scholar]; (b) Yu J, Gaunt MJ, Spencer JB. J Org Chem. 2002;67:4627–4629. doi: 10.1021/jo015880u. [DOI] [PubMed] [Google Scholar]; (c) Petrova KV, Mohr JT, Stoltz BM. Org Lett. 2009;11:293–295. doi: 10.1021/ol802410t. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.For mechanistic studies involving PdCl2(RCN)2 catalyzed alkene isomerization, see:; Schmidt A, Nödling AR, Hilt G. Angew Chem, Int Ed. 2015;54:801–804. doi: 10.1002/anie.201409902. [DOI] [PubMed] [Google Scholar]; For alternative Pd-catalyzed alkene isomerization conditions attempted and a comprehensive review, see:; Lim HJ, Smith CR, RajanBabu TV. J Org Chem. 2009;74:4565–4572. doi: 10.1021/jo900180p. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Travis BR, Narayan RS, Borhan B. J Am Chem Soc. 2002;124:3824–3825. doi: 10.1021/ja017295g. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
